trial

HDAC Inhibitor Augmentation to Clozapine

NCTId NCT03263533
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Early Phase 1 · Withdrawn
Enrollment 0 (actual)
Sponsored by Virginia Commonwealth University
Primary completion 2019-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Early Phase 1
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2017-04
Primary completion
2019-02
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Vorinostat Oral Capsule Group 1Vorinostat Oral Capsule Group 2

Sponsors

Virginia Commonwealth UniversityLead Sponsor

Investigators

1
Javier Gonzalez-Maeso, PhDPrincipal Investigator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
0
Phase
EARLY_PHASE1
Primary Completion Date
2019-02
Status
WITHDRAWN
relationships
The graph out of here
drug
Vorinostat Oral Capsule Group 1
drug
Vorinostat Oral Capsule Group 2
drug
lead_sponsor
Virginia Commonwealth University
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Javier Gonzalez-Maeso, PhD
person